MX2012000752A - Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos. - Google Patents
Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos.Info
- Publication number
- MX2012000752A MX2012000752A MX2012000752A MX2012000752A MX2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A MX 2012000752 A MX2012000752 A MX 2012000752A
- Authority
- MX
- Mexico
- Prior art keywords
- prodrug
- opioid
- amino acid
- gastrointestinal side
- opioids
- Prior art date
Links
- 229940002612 prodrug Drugs 0.000 title abstract 7
- 239000000651 prodrug Substances 0.000 title abstract 7
- 229940005483 opioid analgesics Drugs 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- -1 carbamate amino acid Chemical class 0.000 title 1
- 239000000014 opioid analgesic Substances 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- 230000002496 gastric effect Effects 0.000 abstract 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 1
- JLICHNCFTLFZJN-HNNXBMFYSA-N meptazinol Chemical compound C=1C=CC(O)=CC=1[C@@]1(CC)CCCCN(C)C1 JLICHNCFTLFZJN-HNNXBMFYSA-N 0.000 abstract 1
- 229960000365 meptazinol Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/04—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with only hydrogen atoms, halogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Abstract
Se proporcionan profármacos ligados a carbamato de meptazinol y otros analgésicos opioides. La porción de profármaco puede comprender un aminoácido sencillo o péptido corto. Adicionalmente, la presente invención se refiere a métodos para reducir efectos colaterales gastrointestinales en un sujeto, los efectos colaterales gastronintestinales se asocian con la administración de un analgésico opioide. Los métodos comprenden administrar oralmente un profármaco opiolde o sal farmacéuticamente aceptable del mismo a un sujeto, en donde el profármaco opioide comprende un analgésico covalentemente enlazado a través de una ligadura carbamato a una porción de profármaco, y en donde durante la administración oral, el profármaco o sal farmacéuticamente aceptable minimiza al menos un efecto colateral gastrointestinal asociado con administración oral del analgésico opioide solo. También se proporcionan composiciones para uso con el método.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US27118509P | 2009-07-17 | 2009-07-17 | |
| PCT/IB2010/001747 WO2011007247A1 (en) | 2009-07-17 | 2010-07-16 | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012000752A true MX2012000752A (es) | 2012-05-08 |
Family
ID=42768038
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012000752A MX2012000752A (es) | 2009-07-17 | 2010-07-16 | Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20120270847A1 (es) |
| EP (1) | EP2453900A1 (es) |
| JP (1) | JP2013527124A (es) |
| KR (1) | KR20120060203A (es) |
| AU (1) | AU2010272233A1 (es) |
| BR (1) | BR112012001164A2 (es) |
| CA (1) | CA2767987A1 (es) |
| MX (1) | MX2012000752A (es) |
| RU (1) | RU2012105460A (es) |
| WO (1) | WO2011007247A1 (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2009305563C1 (en) | 2008-10-17 | 2015-09-03 | Signature Therapeutics, Inc. | Pharmaceutical compositions with attenuated release of phenolic opioids |
| PH12012500485A1 (en) | 2009-09-08 | 2012-10-22 | Signature Therapeutics Inc | Compositions comprising enzyme-cleavable ketone-modified opioid prodrugs and optional inhibitors thereof |
| US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
| US20130059914A1 (en) | 2010-04-21 | 2013-03-07 | Signature Therapeutics, Inc. | Compositions Comprising Enzyme-Cleavable Amphetamine Prodrugs and Inhibitors Thereof |
| US8569228B2 (en) | 2011-01-11 | 2013-10-29 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
| EP2683394B1 (en) * | 2011-03-09 | 2021-01-06 | Signature Therapeutics, Inc. | Active agent prodrugs with heterocyclic linkers |
| LT2701707T (lt) | 2011-04-29 | 2021-01-25 | Rutgers, The State University Of New Jersey | Diskinezijos gydymo būdas |
| US10736889B2 (en) | 2011-04-29 | 2020-08-11 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| US9918980B2 (en) | 2011-04-29 | 2018-03-20 | Rutgers, The State University Of New Jersey | Method of treating dyskinesia |
| WO2013128378A1 (en) * | 2012-02-28 | 2013-09-06 | Piramal Enterprises Limited | Phenyl alkanoic acid derivatives as gpr agonists |
| ES2784690T3 (es) | 2013-12-05 | 2020-09-29 | Univ Bath | Nuevos compuestos opioides y sus usos |
| US11634384B2 (en) | 2014-11-25 | 2023-04-25 | Concentric Analgesics, Inc. | Prodrugs of phenolic TRPV1 agonists |
| CN109562281B (zh) | 2016-05-25 | 2021-12-17 | 同心镇痛药物公司 | 酚类trpv1激动剂的前药与局部麻醉药和血管收缩剂联合用于改善局部麻醉 |
| CN108698980B (zh) * | 2016-11-17 | 2021-05-07 | 上海海雁医药科技有限公司 | 苯并二环烷烃衍生物、其制法及其用途 |
| US10799496B2 (en) | 2018-07-13 | 2020-10-13 | Alkermes Pharma Ireland Limited | Naphthylenyl compounds for long-acting injectable compositions and related methods |
| WO2020012245A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Thienothiophene-naltrexone prodrugs for long-acting injectable compositions |
| AU2019310118A1 (en) | 2018-07-27 | 2021-03-11 | Concentric Analgesics, Inc. | Pegylated prodrugs of phenolic TRPV1 agonists |
| US11186585B2 (en) | 2018-08-17 | 2021-11-30 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| US10975099B2 (en) | 2018-11-05 | 2021-04-13 | Alkermes Pharma Ireland Limited | Thiophene compounds for long-acting injectable compositions and related methods |
| CA3149152A1 (en) | 2019-08-11 | 2021-02-18 | Kappa-Pharma LLC | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates |
| AU2021206252A1 (en) | 2020-01-10 | 2022-07-28 | Trevi Therapeutics, Inc. | Methods of administering nalbuphine |
| WO2023055830A1 (en) | 2021-09-29 | 2023-04-06 | Ensysce Biosciences, Inc. | Enzyme-cleavable methadone prodrugs and methods of use thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19602961A1 (de) * | 1995-12-20 | 1997-07-31 | Nycomed Arzneimittel Gmbh | Neue Dihydromorphinderivate, Verfahren zu deren Herstellung und deren Verwendung |
| US6716452B1 (en) | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
| DE60105023T2 (de) | 2000-06-28 | 2005-08-18 | Smithkline Beecham P.L.C., Brentford | Nassvermahlungsverfahren |
| WO2003020200A2 (en) | 2000-11-16 | 2003-03-13 | New River Pharmaceuticals Inc. | A novel pharmaceutical compound and methods of making and using same |
| US20070060500A1 (en) | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
| IL163667A0 (en) | 2002-02-22 | 2005-12-18 | New River Pharmaceuticals Inc | Novel sustained release pharmaceutical compounds to preventabuse of controlled substances |
| AU2004277400B2 (en) | 2003-09-30 | 2009-01-22 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
| WO2007030577A2 (en) | 2005-09-08 | 2007-03-15 | Shire Llc | Prodrugs of t3 and t4 with enhanced bioavailability |
| EP2007762A2 (en) | 2006-04-10 | 2008-12-31 | Shire LLC | Mono and di-substituted oxycodone compounds and compositions |
| US20090192095A1 (en) * | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
-
2010
- 2010-07-16 BR BR112012001164A patent/BR112012001164A2/pt not_active Application Discontinuation
- 2010-07-16 MX MX2012000752A patent/MX2012000752A/es not_active Application Discontinuation
- 2010-07-16 AU AU2010272233A patent/AU2010272233A1/en not_active Abandoned
- 2010-07-16 WO PCT/IB2010/001747 patent/WO2011007247A1/en not_active Ceased
- 2010-07-16 EP EP10743230A patent/EP2453900A1/en not_active Withdrawn
- 2010-07-16 RU RU2012105460/04A patent/RU2012105460A/ru unknown
- 2010-07-16 KR KR1020127003869A patent/KR20120060203A/ko not_active Withdrawn
- 2010-07-16 JP JP2012520120A patent/JP2013527124A/ja active Pending
- 2010-07-16 US US13/383,831 patent/US20120270847A1/en not_active Abandoned
- 2010-07-16 US US12/837,788 patent/US20110015182A1/en not_active Abandoned
- 2010-07-16 CA CA2767987A patent/CA2767987A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012001164A2 (pt) | 2016-03-01 |
| RU2012105460A (ru) | 2013-08-27 |
| JP2013527124A (ja) | 2013-06-27 |
| US20110015182A1 (en) | 2011-01-20 |
| EP2453900A1 (en) | 2012-05-23 |
| WO2011007247A8 (en) | 2012-07-19 |
| US20120270847A1 (en) | 2012-10-25 |
| WO2011007247A1 (en) | 2011-01-20 |
| CA2767987A1 (en) | 2011-01-20 |
| KR20120060203A (ko) | 2012-06-11 |
| AU2010272233A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2012000752A (es) | Profármarcos novedosos de péptidos y aminoácidos de carbamato de opioides y usos de los mismos. | |
| WO2009092073A3 (en) | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects | |
| WO2008131056A3 (en) | Sustained release monoeximic formulations of opioid and nonopioid analgesics | |
| MX2010006284A (es) | Formulaciones farmaceuticas de fenilefrina y composiciones para la absorcion transmucosal. | |
| WO2008131057A3 (en) | Sustained release formulations of opioid and nonopioid analgesics | |
| MY149731A (en) | Compounds | |
| EA031157B9 (ru) | Вводимая перорально кортикостероидная композиция | |
| WO2010065709A3 (en) | Hydroxamic acid derivatives, preparation and therapeutic uses thereof | |
| WO2008024435A3 (en) | Dendritic molecular intracellular transporters and methods of making and using same | |
| NZ703564A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| WO2012054500A3 (en) | Compositions for drug administration | |
| WO2010065950A3 (en) | Albumin binding peptide-mediated disease targeting | |
| MY156913A (en) | Oral administration of peripherally-acting opioid antagonists | |
| UA93709C2 (ru) | 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций | |
| WO2011060104A3 (en) | Compositions and methods for inhibiting cellular adhesion or directing diagnostic or therapeutic agents to rgd binding sites | |
| GB2501219A (en) | Orally bioavailable peptide drug compositions and methods thereof | |
| UA99914C2 (ru) | Способ применения антагонистов вазопресина со средствами антрациклиновой химиотерапии для снижения кардиотоксичности | |
| NZ600583A (en) | Visfatin therapeutic agents for the treatment of acne and other conditions | |
| PL2205279T3 (pl) | Farmaceutyczna kombinacja aliskirenu i walsartanu | |
| PH12013500784A1 (en) | Pharmaceutical compositions comprising nano size droplets of skin whitening agents | |
| ZA200807027B (en) | Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | |
| WO2010012459A3 (en) | A process for the preparation of solifenacin salts and their inclusion into pharmaceutical dosage forms | |
| EA200870182A1 (ru) | Применение комбинации морфина и по меньшей мере одного антагониста опиатов для лечения зависимости от опиатов для предотвращения непероральной опиатомании у наркоманов | |
| WO2007110765A3 (en) | Processes for the preparation of octreotide | |
| WO2012166891A3 (en) | Mu-opioid receptor binding compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |